Videos

An expert on HER2+ breast cancer discusses exciting advancements in the treatment landscape, highlighting the DESTINY-Breast03 trial and trastuzumab deruxtecan.

Lova Sun, MD, MSCE, discusses targeted therapies for NTRK and RET alterations in thyroid cancers.

David L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.

Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.

Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.

Examining the efficacy and safety findings from recent studies on ibrutinib, ruxolitinib, and Belumosudil for chronic GvHD, and their implications for treatment choices.

Regina Barragan-Carrillo, MD, discusses an abstract which evaluated the association between thymectomy and incidence of renal cell carcinoma.

Rebecca A. Shatsky, MD, discusses the KATHERINE trial investigating adjuvant trastuzumab emtansine (T-DM1) in patients with residual invasive HER2+ breast cancer following neoadjuvant therapy.

Dr Shatsky discusses pertuzumab as a treatment for patients with HER2+ breast cancer, highlighting its mechanism of action as a HER2 dimerization inhibitor and updated data from the APHINITY trial.

Kim N. Chi, MD, FRCPC, discusses the significance of the phase 3 MAGNITUDE trial, including its evaluation on patient-reported outcomes, in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer.

Dr. McCloskey discusses the limitations of current treatment options for BPDCN, as well as the emerging research and data that are most anticipated in the field.

Dr. McCloskey explores how various treatments for BPDCN impact the quality of life of patients, both in terms of disease response and side effects.

Dr. McCloskey discusses the general principles and practices for monitoring and mitigating adverse events, particularly capillary leak syndrome (CLS), in BPDCN patients treated with systemic agents like tagraxofusp.

Dr. McCloskey examines the potential of anti-CD123 CAR T-cell therapy for BPDCN, including the main challenges and limitations of this therapeutic approach.

Dr. McCloskey discusses the recent clinical trial results, such as the CADENZA trial, on the efficacy and safety of tagraxofusp in BPDCN patients.

Dr. McCloskey explores the mechanism of action and potential efficacy of tagraxofusp in the treatment of BPDCN.

Dr. McCloskey discusses the appropriateness of the initial therapy (tagraxofusp) based on NCCN guidelines, as well as the benefits and limitations of current treatment regimens for BPDCN.

Dr. McCloskey provides a brief overview of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including the clinical hallmarks of the disease and the challenges in recognizing and diagnosing this rare condition.

Lova Sun, MD, discusses the importance of identifying genetic alterations in thyroid cancer, including RET and NTRK alterations.

Neal Shore, MD, FACS, concludes by addressing the remaining unmet needs in the management of non-metastatic castration-resistant prostate cancer.

Neal Shore, MD, FACS, explains how he integrates findings from the ARAMIS trial to inform patient treatment decisions while prioritizing patient values and personal preferences.

Neal Shore, MD, FACS, outlines his treatment approach, which favors single agents over combination therapies, and incorporates bone-health drugs, vitamins, nutrition guidance, and exercise recommendations to support patients. While PSA remains a valuable biomarker in prostate cancer, he notes that ctDNA and aspects of MRD are gaining importance, although not yet widely adopted.

Saad Z. Usmani, MD, MBA, FACP, FASCO, delves into the development of new treatments for patients with multiple myeloma.

David L. Bartlett, MD, discusses the benefits of genomic testing for patients with cancer and how the approach to genomic testing has changed over the years.

Dr. Motzer discusses the future of nccRCC management and emerging data or unmet needs he is following.

Discussing the appropriateness of the initial therapy based on the NCCN guidelines for the given patient case.

Neal Shore, MD, FACS provides an analysis of the ARAMIS, SPARTAN, and PROSPER trials, which demonstrate improved survival in high-risk non-metastatic castration-resistant prostate cancer through early intervention, highlighting the potential for preventing disease progression based on the data from these pivotal studies.

Exploring the main treatment goals and current first-line and second-line treatment options for patients with chronic GvHD.

Neal Shore, MD, FACS, reviews the case of a 75-year-old man with non-metastatic castration-resistant prostate cancer, seeks to evaluate the timeline of rising PSA to determine the aggressiveness of the disease, and considers the patient an excellent candidate for antigen receptor pathway inhibition.

Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.